AstraZeneca, Amgen tap Brand Institute in new naming twist for their freshly approved Tezspire

There’s certainly no shortage of respiratory drugs on the market. So, when it comes to naming a new brand, there’s extra pressure to be unique to stand out from a large pack while still hitting key linguistic connections.

This was the task handed to pharma product naming service the Brand Institute, which worked with partners AstraZeneca and Amgen for their newly approved asthma drug Tezspire (tezepelumab-ekko).